CW

Cecilia Washburn

Project Manager at Aitia

Cecilia Washburn has a diverse work experience in the field of project management and laboratory research. Cecilia started their career as a Laboratory Technician I at Massachusetts General Hospital in 2011, where they designed and conducted experiments, performed statistical analyses, and trained and supervised interns. In 2013, they worked as a Biological Science Technician at the U.S. Forest Service. From 2014 to 2016, they held the role of Laboratory Technician II at Massachusetts General Hospital, optimizing research protocols and performing lab tests for clinical trials. From 2016 to 2019, they worked at GNS Healthcare, initially as a Research Assistant supporting project managers and then as a Project Manager and Associate Project Manager. In these roles, they created and executed project plans, coordinated activities across multiple projects, facilitated communication and issue resolution, and managed client communications. Since 2019, they have been working as a Project Manager at Harvard Medical School.

Cecilia Washburn earned a Bachelor of Arts (B.A.) degree in Biology/Biological Sciences from Mount Holyoke College, where they attended from 2007 to 2011. In terms of additional certifications, they obtained a certification in "Object-Oriented Data Structures in C++" from Coursera in August 2019. Cecilia also completed certifications in "Cleaning Data in R" and "Intermediate R" from DataCamp, although the specific months and years of completion are not provided.

Location

Cambridge, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Aitia

1 followers

Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.


Industries

Employees

51-200

Links